ACE Gen polimorfizmi aracılığıyla meme kanseri ve renin anjiyotensin sistemi arasındaki ilişki

Abstract

Amaç: Kardiyovasküler sistemin düzenlenmesi, renin-anjiyotensin sistemi (RAS) tarafından önemli ölçüde etkilenir. RAS enzimleri plazma ile sınırlı olmayıp çeşitli organ sistemlerinde de bulunur. Çalışmalar, kanserli tümörlerde lokal RAS ekspresyonunun varlığını giderek daha fazla ortaya koymaktadır. Bu polimorfizmin dolaşımdaki ACE düzeylerini etkilediği bilinmektedir ve bu da kanser gelişimi ile ilişkili olanlar da dahil olmak üzere çeşitli fizyolojik süreçleri etkileyebilir. Çok sayıda çalışmaya rağmen, ACE insersiyon/delesyon polimorfizmi ile meme kanseri riski arasındaki ilişki tartışmalı olmaya devam etmektedir. Bu çalışma, bu ilişkiyi daha net bir şekilde anlamak için Türk popülasyonunda tümörlü ve normal grupları karşılaştırmayı amaçlamaktadır. Bu çalışmanın amacı, 25 tümörlü hasta ve 25 kontrol grubu üzerinde ACE insersiyon/delesyon gen polimorfizmleri ile meme kanseri riski arasındaki ilişkiyi araştırmaktı. Metod: Bu mutasyon, Alu dizisi eklendiğinde bir ekleme (I) ve yok olduğunda bir silme (D) ile sonuçlanır. Bulgular: Homozigot delesyon (DD) mutasyonları olan bireyler, homozigot insersiyon (II) olanlara kıyasla plazma ve dokuda yaklaşık iki kat daha fazla ACE seviyesi sergilerken, heterozigotlar (ID) orta düzeyde seviyeler gösterir. ACE geninin işlev görebilmesi için, anjiyotensin I'in anjiyotensin II'ye dönüştürülmesi ve bradikininin deaktive edilmesi gerekir. Araştırmalar, anjiyotensin II'nin çok önemli roller ve işlevleri olduğunu ortaya koymuştur. Anjiyotensin II, promitotik, proliferatif ve anjiyojenik etkiler gösterebilir. Sonuç: Bu işlevlerin en önemlisi, Ang II tip I reseptörü aracılığıyla tümör hücrelerinin büyümesi ve çoğalmasıdır.

Keywords

• Renin-anjiyotensin sistemi
• ACE geni
• ekleme/silme polimorfizmi

Relationship of breast cancer and renin angiotensin system through ACE gene polymorphism

Abstract

Abstract Purpose: The cardiovascular system's regulation is significantly influenced by the renin-angiotensin system(RAS). RAS enzymes are not limited to plasma but are also found in various organ systems. Studies have increasingly demonstrated the presence of local RAS expression in cancerous tumors. This polymorphism is known to affect circulating ACE levels, which in turn may influence various physiological processes, including those associated with cancer development. Despite numerous studies, the association of ACE insertion/deletion polymorphism and risk of breast cancer remains controversial. This study aims to compare tumor and normal groups in the Turkish population to gain a clearer understanding of this association. The aim of this study was to investigate the association between ACE insertion/deletion gene polymorphisms and breast cancer risk in 25 patients with tumors and 25 controls. Method: This mutation results in an insertion (I) when the Alu sequence is inserted and a deletion(D) when it is absent. Findings: Individuals with homozygous deletion(DD) mutations exhibit approximately double the ACE levels in plasma and tissue compared to those with homozygous insertion(II), while heterozygotes(ID) show intermediate levels. For the ACE gene to function, angiotensin I must be converted to anyiontensin II and bradykinin must be deactivated. Research has revealed that angiotensin II has very important roles and functions. Angiotensin II can exert promitotic, proliferative and angiogenic effects. Conclusion: The most important of these functions is in the growth and proliferation of tumor cells through the Ang II type I receptor.

Keywords

• Renin-angiotensin system
• ACE gene
• insertion/deletion polymorphism

References

1. [1] Ruiter, R., Visser, L. E., van Duijn, C. M., & Stricker, B. H. Ch. (2011). The ACE insertion/deletion polymorphism and risk of cancer: A review and meta-analysis of the literature. Current Cancer Drug Targets, 11(4), 421–430. https://doi.org/10.2174/156800911795538147
2. [2] Eroğlu, O., Zileli, R., Nalbant, M. A., & Ulucan, K. (2018). Prevalence of alpha actinin-3 gene (ACTN3) R577X and angiotensin converting enzyme (ACE) insertion/deletion gene polymorphisms in national and amateur Turkish athletes. Cellular and Molecular Biology, 64(5), 24–28. https://doi.org/10.14715/cmb/2018.64.5.4
3. [3] Lyall, F., Dornan, E. S., McQueen, J., Boswell, F., & Kelly, M. (1992). Angiotensin II increases proto-oncogene expression and phosphoinositide turnover in vascular smooth muscle cells via the angiotensin II AT1 receptor. Journal of Hypertension, 10(12), 1463–1469. https://doi.org/10.1097/00004872-199210120-00005
4. [4] Koh, W. P., Yuan, J. M., Sun, C. L., van den Berg, D., Seow, A., Lee, H. P., & Yu, M. C. (2003). Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Research, 63(3), 573–578.
5. [5] Xi, B., Zeng, T., Liu, L., Liang, Y., Liu, W., Hu, Y., & Li, J. (2011). Association between polymorphisms of the renin-angiotensin system genes and breast cancer risk: A meta-analysis. Breast Cancer Research and Treatment, 130(2), 561–568. https://doi.org/10.1007/s10549-011-1602-3
6. [6] Dastgheib, S. A., Asadian, F., Farbod, M., Karimi-Zarchi, M., Meibodi, B., Akbarian, E., & Neamatzadeh, H. (2020). Association of ACE I/D, -240A>T and AT1R A1166C polymorphisms with susceptibility to breast cancer: A systematic review and meta-analysis based on 35 case-control studies. Nucleosides, Nucleotides & Nucleic Acids, 40(1), 117–135. https://doi.org/10.1080/15257770.2020.1826515
7. [7] Pei, X. H., & Li, H. X. (2012). Insertion/deletion (I/D) in the angiotensin-converting enzyme gene and breast cancer risk: Lack of association in a meta-analysis. Asian Pacific Journal of Cancer Prevention, 13(11), 5633–5636. https://doi.org/10.7314/apjcp.2012.13.11.5633
8. [8] Moghimi, M., Kargar, S., Jafari, M. A., Ahrar, H., Jarahzadeh, M. H., Neamatzadeh, H., & Sadeghizadeh-Yazdi, J. (2018). Angiotensin-converting enzyme insertion/deletion polymorphism is associated with breast cancer risk: A meta-analysis. Asian Pacific Journal of Cancer Prevention, 19(11), 3225–3231. https://doi.org/10.31557/APJCP.2018.19.11.3225

9. [9] Haiman, C. A., Henderson, S. O., Bretsky, P., Kolonel, L. N., & Henderson, B. E. (2003). Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: The multiethnic cohort. Cancer Research, 63(20), 6984–6987.
10. [10] González-Zuloeta Ladd, A. M., Arias Vásquez, A., Sayed-Tabatabaei, F. A., Coebergh, J. W., Hofman, A., Njajou, O., Stricker, B., & van Duijn, C. (2005). Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiology, Biomarkers & Prevention, 14(9), 2143–2146. https://doi.org/10.1158/1055-9965.EPI-05-0045
11. [11] Li, X., Zheng, Z., Qu, H., Chen, J., & Li, G. (2015). Lack of association of angiotensin-converting enzyme insertion/deletion polymorphism with breast cancer: An updated meta-analysis based on 10,405 subjects. Journal of the Renin-Angiotensin-Aldosterone System, 16(4), 1095–1100. https://doi.org/10.1177/1470320314555474
12. [12] Essobky, H., Abdel-Megied, A. E., El-Mezayen, H., & El-Sayed, M. (2022). Correlation of ACE I/D (rs1799752) polymorphism with breast cancer variants and prognostic markers in Egyptian patients. American Journal of Biochemistry and Molecular Biology, 10(3), 8–22.
13. [13] Alves Corrêa, S. A., Ribeiro de Noronha, S. M., Nogueira-de-Souza, N. C., Valleta de Carvalho, C., Massad Costa, A. M., Juvenal Linhares, J., Vieira Gomes, M. T., & Guerreiro da Silva, I. D. C. (2009). Association between the angiotensin-converting enzyme (insertion/deletion) and angiotensin II type 1 receptor (A1166C) polymorphisms and breast cancer among Brazilian women. Journal of the Renin-Angiotensin-Aldosterone System, 10(1), 51–58. https://doi.org/10.1177/1470320309102317
14. [14] Sharique, O. A., & Shobana, M. (2021). Role of ACE I/D polymorphism in breast cancer in Northern Indian women. Annals International Medical and Dental Research, 5(6), 22–27.
15. [15] Said, R., & Zoubeidi, T. (2022). First report on relationship between ACE I/D polymorphism and breast cancer risk in a North African population. Journal of Clinical Laboratory Analysis, 36(9), e24613. https://doi.org/10.1002/jcla.24613
16. [16] Sun, M., Liu, C., Wei, F., Zhong, J., & Sun, Y. (2011). Association of angiotensin I-converting enzyme insertion/deletion polymorphism with breast cancer: A meta-analysis. Journal of the Renin-Angiotensin-Aldosterone System, 12(4), 611–616. https://doi.org/10.1177/1470320311405699
17. [17] Van Der Knaap, R., Siemes, C., Coebergh, J. W. W., van Duijn, C. M., Hofman, A., & Stricker, B. H. Ch. (2008). Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The Rotterdam Study. Cancer, 112(4), 748–757. https://doi.org/10.1002/cncr.23215